Conmed Corp Announces Departure of Board Member Martha Aronson

Martha Aronson, a member of Conmed Corp's Board of Directors, is resigning to take on the role of President and Chief Executive Officer at Merit Medical. Her resignation will be effective on July 7, 2025. Aronson has been a key contributor to Conmed's strategic growth and governance, and her transition highlights the strength of the company's leadership development. However, her departure could lead to a temporary gap in leadership and strategic direction.

Largo, Fla., July 07, 2025 -- CONMED Corporation (NYSE: CNMD) announced today that Martha Aronson will be stepping down from the company’s Board of Directors to assume the role of President and Chief Executive Officer at Merit Medical, a global leader in the development, manufacture, and distribution of proprietary medical devices. Ms. Aronson's resignation from the Board will be effective July 7, 2025, as she transitions to her new leadership responsibilities.

Ms. Aronson has been a key contributor to CONMED's strategic growth and governance, serving on the Board since February 2016 and holding various leadership positions, including as Chair of the Board. Her tenure has been marked by a focus on strategic growth, governance excellence, and a deep commitment to the company’s mission and values.

The transition comes at a time when CONMED is experiencing robust growth, with its products used by surgeons and other healthcare professionals across various specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Despite the departure of a key board member, CONMED remains well-positioned with a strong leadership team in place.

The appointment of Ms. Aronson at Merit Medical Systems (NASDAQ: MMSI) is seen as a significant milestone for the company, which has been led by founder Fred Lampropoulos since its inception in 1987. Lampropoulos will transition from his role as President and CEO to continue serving as Chairman of the Board, ensuring continuity and institutional knowledge while allowing for fresh operational leadership.

Ms. Aronson brings extensive healthcare experience, having managed global businesses worth $500M-$1B at companies including Ecolab and Hill-Rom. Her appointment coincides with strong preliminary Q2 2025 revenue of $380-384 million, representing a 12-14% increase year-over-year. The company will release complete Q2 2025 financial results on July 30, 2025.

The transition at Merit Medical appears well-planned, with a three-month transition period allowing for a smooth handover. This strategic move indicates a focus on organic growth and cultural fit, rather than dramatic strategic shifts. The appointment of Ms. Aronson, who has served on multiple medical device company boards, demonstrates the company's commitment to industry expertise and governance excellence.

References:
[1] https://finance.yahoo.com/news/martha-aronson-step-down-conmed-210000941.html
[2] https://www.stocktitan.net/news/MMSI/merit-medical-names-martha-aronson-as-new-president-and-chief-c0v0wza4zszd.html